A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Trial Profile

A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Thrombocytopenia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 22 Dec 2015 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 22 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top